ORIC-114 not checked

ORIC Pharmaceuticals

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection”In the company’s words, NCT06816992 on ClinicalTrials.gov
Tested for
Solid Tumors (2 trials), EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
Main trialPhase 1/2
“The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.”In the company’s words, NCT05315700 on ClinicalTrials.gov

Other drugs for Solid Tumors

All 2439 drugs for Solid Tumors

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jun 2027 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Phase 1Recruiting Dec 2026 ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Phase 1Completed 23 Nov 2023 Effect of Food on the Pharmacokinetics of ORIC-114
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ORIC-114

Following is part of Solo: you see every change to ORIC-114 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in